{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:44Z","timestamp":1790806844853,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.ajo.2012.06.010","type":"journal-article","created":{"date-parts":[[2012,9,8]],"date-time":"2012-09-08T11:45:17Z","timestamp":1347104717000},"page":"150-158.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["An Updated Study of the Use of Bevacizumab in the Treatment of Patients with Prethreshold Retinopathy of Prematurity in Taiwan"],"prefix":"10.1016","volume":"155","author":[{"given":"Wei-Chi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsi-Kung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ting","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-May","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San-Ni","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ajo.2012.06.010_bib1","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm1095-1024","article-title":"Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity","volume":"1","author":"Alon","year":"1995","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.ajo.2012.06.010_bib2","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2012.06.010_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/archopht.124.1.24","article-title":"Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP)","volume":"124","author":"Repka","year":"2006","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2012.06.010_bib4","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/archopht.1996.01100140287005","article-title":"Partial retinal detachment at 3 months after threshold retinopathy of prematurity","volume":"114","author":"Gilbert","year":"1996","journal-title":"Arch Ophthalmol"},{"issue":"3 suppl","key":"10.1016\/j.ajo.2012.06.010_bib5","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1097\/IAE.0b013e318158ea0e","article-title":"Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity","volume":"28","author":"Wu","year":"2008","journal-title":"Retina"},{"issue":"23","key":"10.1016\/j.ajo.2012.06.010_bib6","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajo.2012.06.010_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ajo.2009.02.006","article-title":"Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study","volume":"148","author":"Bashshur","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2012.06.010_bib8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","article-title":"Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.ajo.2012.06.010_bib9","doi-asserted-by":"crossref","first-page":"1695.e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2012.06.010_bib10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ajo.2006.04.058","article-title":"Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy","volume":"142","author":"Mason","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2012.06.010_bib11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","article-title":"Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.ajo.2012.06.010_bib12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1600-0420.2007.01107.x","article-title":"Intravitreal bevacizumab for vitreous haemorrhage","volume":"86","author":"Jonas","year":"2008","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2012.06.010_bib13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-0420.2007.01021.x","article-title":"Intravitreal bevacizumab in recurrent diabetic vitreous haemorrhage after vitrectomy","volume":"86","author":"Ruiz-Moreno","year":"2008","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2012.06.010_bib14","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ajo.2006.06.066","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma","volume":"142","author":"Iliev","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2012.06.010_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00417-008-0916-2","article-title":"One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion","volume":"247","author":"Jaissle","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2012.06.010_bib16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bjo.2008.141085","article-title":"Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion\u201412-month results of a prospective clinical trial","volume":"93","author":"Prager","year":"2009","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2012.06.010_bib17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/bjo.2007.127282","article-title":"Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study","volume":"92","author":"Kriechbaum","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2012.06.010_bib18","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.ophtha.2009.04.026","article-title":"Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity","volume":"116","author":"Sato","year":"2009","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2012.06.010_bib19","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.ophtha.2008.12.023","article-title":"Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity","volume":"116","author":"Sato","year":"2009","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2012.06.010_bib20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajo.2012.06.010_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","article-title":"Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan","volume":"118","author":"Wu","year":"2011","journal-title":"Ophthalmology"},{"issue":"3 suppl","key":"10.1016\/j.ajo.2012.06.010_bib22","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":"Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity","volume":"28","author":"Lalwani","year":"2008","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.ajo.2012.06.010_bib23","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II","volume":"28","author":"Mintz-Hittner","year":"2008","journal-title":"Retina"},{"issue":"3 suppl","key":"10.1016\/j.ajo.2012.06.010_bib24","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":"Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity","volume":"28","author":"Quiroz-Mercado","year":"2008","journal-title":"Retina"},{"issue":"11","key":"10.1016\/j.ajo.2012.06.010_bib25","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2012.06.010_bib26","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archophthalmol.2008.1","article-title":"Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study","volume":"126","author":"Kong","year":"2008","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2012.06.010_bib27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/IAE.0b013e31818a1ee7","article-title":"Off-label use of bevacizumab in retinopathy of prematurity","volume":"29","author":"Rishi","year":"2009","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.ajo.2012.06.010_bib28","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"38","author":"Travassos","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"4","key":"10.1016\/j.ajo.2012.06.010_bib29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4103\/0301-4738.33057","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"55","author":"Azad","year":"2007","journal-title":"Indian J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2012.06.010_bib30","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","article-title":"Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity","volume":"245","author":"Chung","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2012.06.010_bib31","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1089\/jop.2011.0060","article-title":"Intravitreal bevacizumab for retinopathy of prematurity","volume":"27","author":"Harder","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ajo.2012.06.010_bib32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4103\/0974-9233.80716","article-title":"Early experience with intravitreal bevacizumab combined with laser treatment for retinopathy of prematurity","volume":"18","author":"Raizada","year":"2011","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2012.06.010_bib33","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/IAE.0b013e31820d4000","article-title":"Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity","volume":"31","author":"Axer-Siegel","year":"2011","journal-title":"Retina"},{"issue":"suppl 3","key":"10.1016\/j.ajo.2012.06.010_bib34","first-page":"S15","article-title":"Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (AP-ROP)","volume":"94","author":"Wutthiworawong","year":"2011","journal-title":"J Med Assoc Thai"},{"issue":"6","key":"10.1016\/j.ajo.2012.06.010_bib35","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/IAE.0b013e3181a3b7b1","article-title":"Transconjunctival, sutureless 25-gauge lens sparing vitrectomy for stage 4 retinopathy of prematurity-related retinal detachments","volume":"29","author":"Chan-Kai","year":"2009","journal-title":"Retina"},{"issue":"12","key":"10.1016\/j.ajo.2012.06.010_bib36","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1167\/iovs.08-2584","article-title":"Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture","volume":"49","author":"Smith","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.ajo.2012.06.010_bib37","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0161-6420(01)00695-9","article-title":"Outcomes after laser therapy for threshold retinopathy of prematurity","volume":"108","author":"Foroozan","year":"2001","journal-title":"Ophthalmology"},{"issue":"7 suppl","key":"10.1016\/j.ajo.2012.06.010_bib38","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/01.iae.0000244285.79004.e6","article-title":"Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes","volume":"26","author":"Kychenthal","year":"2006","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.ajo.2012.06.010_bib39","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1395-3907.2003.00171.x","article-title":"Outcome of zone 1 retinopathy of prematurity","volume":"81","author":"O'Keefe","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"issue":"2","key":"10.1016\/j.ajo.2012.06.010_bib40","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ophtha.2008.09.035","article-title":"Astigmatism in the Early Treatment for Retinopathy of Prematurity Study: findings to 3 years of age","volume":"116","author":"Davitt","year":"2009","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2012.06.010_bib41","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ophtha.2007.07.028","article-title":"Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age","volume":"115","author":"Quinn","year":"2008","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2012.06.010_bib42","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0161-6420(96)30487-9","article-title":"Visual fields measured with double-arc perimetry in eyes with threshold retinopathy of prematurity from the cryotherapy for retinopathy of prematurity trial","volume":"103","author":"Quinn","year":"1996","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2012.06.010_bib43","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.ophtha.2011.04.028","article-title":"Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice","volume":"118","author":"Moshfeghi","year":"2011","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2012.06.010_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaapos.2006.01.004","article-title":"Race, gender, and clinical risk index for babies (CRIB) score as predictors of severe retinopathy of prematurity","volume":"10","author":"Yang","year":"2006","journal-title":"J AAPOS"},{"issue":"2","key":"10.1016\/j.ajo.2012.06.010_bib45","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000047189","article-title":"Race, Candida sepsis, and retinopathy of prematurity","volume":"81","author":"Tadesse","year":"2002","journal-title":"Biol Neonate"},{"issue":"2","key":"10.1016\/j.ajo.2012.06.010_bib46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/08820530902800314","article-title":"Retinopathy of prematurity: current concepts in molecular pathogenesis","volume":"24","author":"Heidary","year":"2009","journal-title":"Semin Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2012.06.010_bib47","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0002-9440(10)65004-3","article-title":"Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity","volume":"156","author":"Lashkari","year":"2000","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.ajo.2012.06.010_bib48","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1203\/PDR.0b013e31819d9e8c","article-title":"A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants","volume":"65","author":"Lofqvist","year":"2009","journal-title":"Pediatr Res"},{"issue":"3","key":"10.1016\/j.ajo.2012.06.010_bib49","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1167\/iovs.09-4140","article-title":"Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes","volume":"51","author":"Miyake","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ajo.2012.06.010_bib50","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1167\/iovs.09-4425","article-title":"Long-term tolerability and serum concentration of bevacizumab (Avastin) when injected in newborn rabbit eyes","volume":"51","author":"Wu","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.ajo.2012.06.010_bib51","first-page":"161","article-title":"Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy","volume":"31","author":"Qian","year":"2011","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.ajo.2012.06.010_bib52","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2012.06.010_bib53","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","article-title":"On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment\u2014a review","volume":"100","author":"Hard","year":"2011","journal-title":"Acta Paediatr"},{"issue":"4","key":"10.1016\/j.ajo.2012.06.010_bib54","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ajo.2009.05.031","article-title":"A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity","volume":"148","author":"Micieli","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2012.06.010_bib55","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bjo.2004.045815","article-title":"Treated threshold stage 3 versus spontaneously regressed subthreshold stage 3 retinopathy of prematurity: a study of motility, refractive, and anatomical outcomes at 6 months and 36 months","volume":"89","author":"Sahni","year":"2005","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2012.06.010_bib56","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3341\/kjo.1995.9.2.111","article-title":"Change of refraction in premature infants after cryotherapy for retinopathy of prematurity between the age of six months and three years","volume":"9","author":"Khwarg","year":"1995","journal-title":"Korean J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2012.06.010_bib57","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3928\/0191-3913-19970301-06","article-title":"Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: 3-year outcome","volume":"34","author":"White","year":"1997","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"1","key":"10.1016\/j.ajo.2012.06.010_bib58","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/bjo.81.1.12","article-title":"Cryotherapy and laser treatment for acute retinopathy of prematurity: refractive outcomes, a longitudinal study","volume":"81","author":"Laws","year":"1997","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2012.06.010_bib59","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bjo.82.11.1254","article-title":"Three year visual outcome for treated stage 3 retinopathy of prematurity: cryotherapy versus laser","volume":"82","author":"Pearce","year":"1998","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2012.06.010_bib60","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0161-6420(98)99029-7","article-title":"A comparison of laser photocoagulation with trans-scleral cryotherapy in the treatment of threshold retinopathy of prematurity","volume":"105","author":"Connolly","year":"1998","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2012.06.010_bib61","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1067\/mpa.2002.121452","article-title":"Clinical outcome of confluent laser photoablation for retinopathy of prematurity","volume":"6","author":"Fallaha","year":"2002","journal-title":"J AAPOS"},{"issue":"5","key":"10.1016\/j.ajo.2012.06.010_bib62","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0008-4182(04)80142-X","article-title":"Myopia and astigmatism in retinopathy of prematurity after treatment with cryotherapy or laser photocoagulation","volume":"39","author":"Al-Ghamdi","year":"2004","journal-title":"Can J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2012.06.010_bib63","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bjo.2004.045815","article-title":"Treated threshold stage 3 versus spontaneously regressed subthreshold stage 3 retinopathy of prematurity: a study of motility, refractive, and anatomical outcomes at 6 months and 36 months","volume":"89","author":"Sahni","year":"2005","journal-title":"Br J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939412004412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939412004412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:07:26Z","timestamp":1757596046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939412004412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0002939412004412"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2012.06.010","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Updated Study of the Use of Bevacizumab in the Treatment of Patients with Prethreshold Retinopathy of Prematurity in Taiwan","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2012.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}